

F. No. 19(719)/2016/DP/NPPA/Div.II

भारत सरकार

Government of India

रसायन और उर्वरक मंत्रालय

Ministry of Chemicals & Fertilizers

औषध विभाग

Department of Pharmaceuticals

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

National Pharmaceutical Pricing-Authority

P-61

तीसरी/पांचवी मंजिल 5<sup>th</sup> / 3<sup>rd</sup> Floor,  
वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग  
YMCA Cultural Center Building,  
1, जय सिंह रोड, नई दिल्ली-110001  
1, Jai Singh Road, N. Delhi - 110001.  
दिनांक :- 03.01.2017

OFFICE MEMORANDUM

**Subject: Re-Constitution of Committee of Experts under Drugs (Prices Control) Order, 2013 to recommend fixation of separate ceiling/retail price of formulations which fall under the purview of Para 11(3&4) of DPCO 2013**

The fourth meeting of the committee of Experts constituted under para 11(3 & 4) of DPCO, 2013 is scheduled to be held on **18.01.2017 (Wednesday) at 11.00 AM** in the conference room of National Pharmaceuticals Pricing Authority (NPPA), 3<sup>rd</sup> Floor, YMCA Cultural Center Building, 1, Jai Singh Road, New Delhi - 110001 to consider the cases as on date (Annexure) under the provision contained in Para 11 (3 & 4), which states that:

- (a) Notwithstanding anything contained in sub-paragraphs (1) and (2), in case of injections or inhalation or any other medicine for which dosage form or strength or both are not specified in the Schedule-I of the Drugs (Prices Control) Order, 2013, the Government may fix and notify separate ceiling price or retail price for such formulations with specific therapeutic rationale, considering the type of packaging or pack size or dosage compliance or content in the pack namely liquid, gaseous or any other form, in the unit dosage as the case may be, conforming to Indian Pharmacopoeia or other standards as specified in the Drugs and Cosmetics Act, 1940 (23 of 1940) and the rules made thereunder for the same formulation.
  - (b) The Government shall form a Committee of Experts, as it may deem fit, within a period of fifteen days from the date of issue of this order, to recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the above parameters.
2. Moreover, any other issue(s) relating to above mention subject, with the permission of Chair will also be taken up/discussed in the meeting.
  3. You are, therefore, requested to make it convenient to attend the meeting.

Encl: As above.

To,

The Members of the Committee

Copy to: (for inf. & f.)

1. PPS to Chairman, NPPA
2. PPS to MS, NPPA
3. PPS to Adviser (Cost), NPPA

(ए. के. खुराना)  
निदेशक

F. No. 19(719)/2016/DP/NPPA/Div.II

भारत सरकार

Government of India

रसायन एवं उर्वरक मंत्रालय

Ministry of Chemical and Fertilizers

औषध विभाग

Department of Pharmaceuticals

राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

National Pharmaceutical Pricing Authority

P-2

5<sup>th</sup>/3<sup>rd</sup> Floor,

YMCA cultural Centre Building  
1, Jai Singh Road, N. Delhi- 11001

Dated 03.01.2017

OFFICE MEMORANDUM

**Subject: Re-Constitution of Committee of Experts under Drugs (Prices Control) Order, 2013 to recommend fixation of separate ceiling/retail price of formulations which fall under the purview of Para 11(3&4) of DPCO 2013**

The undersigned is directed to refer to SO 1192(E) dated 22.3.2016, para 11(3 & 4) of DPCO 2013 and this office letter dated 6.4.2016 regarding the constitution of the Committee of Experts under Drugs (Prices Control) Order, 2013. With the approval of the Competent Authority, the Committee of Experts under Para 11(3&4) of DPCO 2013 has been re-constituted as under:

1	Adviser(cost), National Pharmaceutical Pricing Authority	Chairperson
2	Representative of Drug Controller General of India, Ministry of Health and Family Welfare, New Delhi	Member
3	The Head of Department of Cardiology, AIIMS, New Delhi or representative	Member
4	The Head of Department of Medicine, AIIMS, New Delhi or representative	Member
5	Prof. Y. K. Gupta, Head, Department of Pharmacology, AIIMS, New Delhi or representative	Member
6	The Executive Director, National Health System Resource Centre or representative	Member
7	Dr. Sarita Dhawan, Add. Director /Director, CGHS, New Delhi or representative	Member
8	Director, Delhi Institute of Pharmaceutical Science and Research (DIPSR) or representative	Member
9	Shri D. P. Pathak, Director/Director, Indian Council of Medical Research or representative	Member
10	Any other subject specialist(s) / expert(s) co-opted by the committee on case to case basis	Member
11	Director (Pricing), NPPA	Convener

2. Representation by concerned Ex.-officio members/institutions must ensure adequate seniority and expertise of the officers concerned for the required level of knowledge and responsibility.

3. The required quorum to conduct the meeting shall be Chairperson plus four other members (representatives) excluding the convener.

4. The Committee shall recommend fixing of separate ceiling price of scheduled formulations or retail price of a new drug as per the parameters mentioned under para 11(3&4) of DPCO 2013.

sd/-  
(A.K. Khurana)  
Director (Pricing)

To:  
Members of the Committee  
Copy to:  
PPS to Chairman, NPPA,  
PPS to Member Secretary, NPPA

## Representation of companies under para 11(3)

03.01.2016

Sr. No.	Company Name	Formulation	S.O No.	Dated	Recived on
1	Cipla	Budesonide Inhalation 100mcg & 200mcg	1561(E)	27.4.2016	12.7.2016 & 25.11.2016
2	Unimed	Pre- Filled Syringe and Glass Vial packs of Hydroxypropyl Methylcellulose injection 2%	1561(E)	27.4.2016	11.8.2016
3	Aurolab	Hydroxypropyl Methylcellulose injection 2%	1561(E)	27.4.2016	30.8.2016
4	Ipca	Metoclopramide Injection 2ml Ampoul and 10ml vial each containing 5mg/ml			
5	Wockhardt	Dicyclomine Injection	3431(E)	10.11.2016	24.11.2016
6	Glenmark	Digihaler FB 100/200/400 and Budesonide/ Formoterol (100/6, 200/6 and 400/6mcg)			15.12.2016
7	Abbott	Tramadol injection 50mg/ml			
8	IDMA	Small Volume Parenterals			